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Abstract
Extensive studies of BRCA1- and BRCA2-associated breast tumours have been carried out in
the few years since the identification of these familial breast cancer predisposing genes. The
morphological studies suggest that BRCA1 tumours differ from BRCA2 tumours and from
sporadic breast cancers. Recent progress in immunohistochemistry and molecular biology
techniques has enabled in-depth investigation of molecular pathology of these tumours.
Studies to date have investigated issues such as steroid hormone receptor expression,
mutation status of tumour suppressor genes TP53 and c-erbB2, and expression profiles of cell
cycle proteins p21, p27 and cyclin D1. Despite relative paucity of data, strong evidence of
unique biological characteristics of BRCA1-associated breast cancer is accumulating.
BRCA1-associated tumours appear to show an increased frequency of TP53 mutations,
frequent p53 protein stabilization and absence of imunoreactivity for steroid hormone
receptors. Further studies of larger number of samples of both BRCA1- and BRCA2-
associated tumours are necessary to clarify and confirm these observations.
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Introduction
In recent years, studies of familial breast cancers associ-
ated with mutations in BRCA1 and BRCA2 genes have
suggested that these tumours have a characteristic
histopathological phenotype [1••,2•]. Although tumours
associated with BRCA1 and BRCA2 are on average of
higher grade than sporadic breast cancer, there are also dif-
ferences between tumours associated with the two genes.
These data suggest distinct pathways for tumourigenesis.
Significant improvement in our understanding of tumour
biology in recent years has been achieved by immunohisto-
chemical and molecular analyses of cancer-associated genes
and their encoded proteins. Detection of protein expression
in sporadic cancers by immunohistochemistry has enabled
the identification of new markers that have diagnostic, ther-
apeutic and prognostic value. Examples include hormone
[eg oestrogen receptor (ER)] and growth factors receptors
(eg epidermal growth factor receptor), tumour-specific onco-
gene products (eg CerbB2) and cell-cycle proteins (eg cyclin
D1). Molecular analysis of the genetic alterations in tumours
has also been correlated with tumour morphology and
behaviour. A good example is the identification of mutations
in the E-cadherin gene in invasive lobular carcinoma of
breast and diffuse gastric carcinomas that have specific mor-
phology and metastatic patterns [3–5].http://breast-cancer-research.com/vol1no1/27oct99/review/3
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This article reviews the immunohistochemical and molec-
ular data in tumours associated with mutations in BRCA1
and BRCA2 genes. Clearly, this issue is important for more
than just reasons of scientific curiosity, because the phe-
notype of the tumour may provide vital diagnostic and
prognostic information for the patient. In addition, with
the availability of genetic testing for BRCA1 and BRCA2
mutations within high-risk families, the morphological and
molecular phenotype may help to identify patients who
are suitable for mutation testing of specific genes.
To date, most, if not all studies that investigated the mole-
cular profile of BRCA-associated tumours have been per-
formed on relatively small numbers of patients, making
statistical analysis of individual studies difficult. Combined
data from the literature, however, are beginning to provide
a glimpse of the unique immunohistochemical and molec-
ular profile of BRCA1- and BRCA2-associated tumours.
Steroid hormone receptors
Since the discovery of the ER in 1960, it has become one
of the most important prognostic and predictive markers
for breast cancer [6]. It is well known that ER expression
is inversely correlated with tumour grade [7]. BRCA-asso-
ciated tumours, which are more often of higher grade than
that of sporadic breast cancer, would therefore be pre-
dicted to be more often ER negative. Indeed, numerous
studies [8•,9,10••,11••,12•] have shown low levels of ER
expression in familial breast cancers. Osin et al [8•,9] have
shown that when ER was assessed in BRCA-associated
tumours in comparison with a grade-matched control
group, the expression of ER in BRCA1-associated tumours
was still significantly lower (8 versus 26%). In contrast, the
expression of ER in BRCA2-associated tumours appears to
be similar to that in sporadic breast cancers.
The detection of ER immunohistochemically does not nec-
essarily reflect its functional competence, and a certain pro-
portion of tumours that express ER are known to be
resistant to anti-oestrogen therapy. The function of ER is
dependent on the ability to transactivate so-called ER-
dependent genes. Expression of progesterone receptor
(PgR) and PS2 protein is indirect evidence of retained tran-
scriptional activation activity of ER, and it has been shown
that PgR and PS2 expression have stronger correlation with
prognosis in breast cancer than ER expression alone [13].
Osin et al [8•] showed that, although nine out of 40 familial
breast cancer patients were ER positive, only two of these
were also PgR positive (Fig. 1). This suggests that even in
cases where ERs could be identified immunohistochemi-
cally, their functional ability may be compromised.
Another intriguing question is at what stage of progression
do tumours become hormone independent? It has been
demonstrated that both the invasive and in-situ compo-
nent in BRCA-associated tumours have a similar status of
steroid hormone receptor expression, suggesting that loss
of hormonal response is a relatively early event in progres-
sion of these tumours [8•,9]. These data strongly suggest
resistance to anti-oestrogen therapy of BRCA-associated
tumours, and undoubtedly could have very serious practi-
cal implications in view of proposed anti-oestrogen pro-
phylaxis for patients from high-risk families.
c-erbB2
A large number of studies have been performed on the
functional role of c-erbB2 oncogene (HER-2/neu) in breast
cancer. HER-2/neu product is a tyrosine kinase receptor
that belongs to the same family as epidermal growth factor
receptor. It is overexpressed in approximately 20–30% of
high-grade invasive breast cancers and has been shown to
be a valuable prognostic indicator. HER2/neu status also
predicts response to anti-oestrogen and cytotoxic
chemotherapy. Antibodies directed against the HER2/neu
protein have attracted a lot of attention recently because
of the availability of the monoclonal antibody herceptin
for treatment of breast cancer [14]. Clearly, the role of
HER2/neu in familial breast cancer is of interest.
Data on HER2/neu are limited and conflicting. Armes et al
[11••] and Robson et al [12•] have not shown a difference
in HER2/neu expression between sporadic and familial
cancers. The study by Johannsson et al [10••], however,
demonstrated that c-erbB2 expression in BRCA1-associated
cancers is lower than would be predicted on the basis of
their histological grade. Data from a large Breast Cancer
Linkage Consortium study are awaited to clarify this issue.
TP53
P53 protein is one of most important guardians of stability
and integrity of the genome, and acts to prevent cell pro-
liferation after DNA damage and activates apoptosis in
Figure 1
Immunohistochemical staining of BRCA1 tumour for (a) oestrogen
receptor and (b) progesterone receptor.Breast Cancer Research    Vol 1 No 1 Osin and Lakhani
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case of unrepairable damage. Mutations in the TP53 gene
are the most common genetic alterations in human cancers
and are encountered in 20–40% of sporadic breast cancers.
The frequency of these mutations correlates with tumour
grade. Detection of p53 protein by immunohistochemistry
has become a routine method in pathology practice, and
the presence of detectable p53 protein is an important
prognostic marker that correlates with higher histopatho-
logical grade, increased mitotic activity, aggressive tumour
behaviour and therefore a worse prognosis [15,16]. Using
immunohistochemistry, Crook et al [17••] reported that
BRCA-associated tumours were more often p53 positive
than were grade-matched sporadic breast cancers (77%
BRCA1, 45% BRCA2, 35% sporadic) (Fig. 2).
Further evidence for an important role for p53 in familial
breast cancer comes from the detection of mutations at a
higher frequency than in sporadic cancers. The mutations
in BRCA-associated cancers were often multiple and their
locations unusual, which is in marked contrast to sporadic
cancer [17••,18].
Studies of TP53 gene function in BRCA tumours have
been performed using in vitro models. These show that
the identified mutants are unique not only in their
number and location, but also in their function. The
mutants retain some of the wild p53-dependent activities,
such as transactivation, suppression of proliferation and
apoptosis induction (in particular via PIG3 transactiva-
tion). At the same time, these mutants fail to suppress
transformation and they exhibit gain of function [19••].
The retained ability of some of these novel mutants to
transactivate MDM2 may explain the absence of immun-
odetectable p53 in some BRCA-associated tumours with
p53 mutations. This can occur because of degradation of
the p53 protein by the MDM2-regulated, ubiquitin-
depended pathway.
In sporadic breast cancer an inverse correlation between
loss of p53 expression and high proliferation index on one
side, and low expression of the antiapoptotic gene BCL2
on the other has been demonstrated. Surprisingly two
studies [11••,12•] have shown that BRCA1/BRCA2 tumours
have the same level of BCL2 expression as the control
group, despite being highly proliferative and with fre-
quent p53 mutations. Clearly the regulation of both cell
cycle and apoptosis is multifactorial and relatively high
expression of antiapoptotic BCL2 is probably one of the
mechanisms of tumour survival in conditions where apop-
tosis-inducing genes are still transactivated by mutant p53.
Cell cycle proteins
The cyclin-dependent kinase inhibitor p21 blocks transi-
tion from G1 to S phase and suppresses cell proliferation.
The p21 is thought to be a major downstream effector of
the wild-type p53-mediated growth arrest pathway that is
induced by DNA damage. In sporadic breast tumours the
expression of p21 is inversely correlated with p53 expres-
sion and high tumour grade [16,20]. The proposed expla-
nation is that mutated p53 is unable to activate p21
transcription. Immunohistochemical studies [17••] have
failed to demonstrate a relationship between p21 and p53
in BRCA1/BRCA2 tumours, suggesting that p21 transacti-
vation in this group could be mediated by a p53-indepen-
dent mechanism. This finding could be of practical
significance, because there is an increase in p21 expres-
sion and apoptosis in cells with wild-type p53 exposed to
chemotherapy [21].
Another cyclin-dependent kinase complex inhibitor that
plays an important role in breast cancer pathogenesis is
p27. There are reports that patients whose tumours over-
express p27 have significantly higher survival rates. In
small breast cancers (stages T1a and b) p27 expression was
reported as the only independent prognostic factor [22].
Data regarding p27 expression in familial BRCA-associated
breast cancer are scarce and contradictory. Robson et al
[12•] reported that p27 expression does not differ between
sporadic and BRCA-associated cancers. This is contrary to
our own observations, however, where we found p27 to be
overexpressed in BRCA1/BRCA2 breast cancers (86% in
familial tumours versus 65% in sporadic tumours; Osin PP,
unpublished observations). Some studies [23] have
demonstrated a better prognosis for familial breast cancer.
If this is substantiated (and there is evidence that this may
not be correct [24]), the overexpression of p27 could be
one possible explanation.
Cyclin D1 is a regulator of progression from G1 to S phase
in cell cycle. It represents an important part of hormonal
regulation of mammary epithelium growth: cyclin D1 is
known to be upregulated by oestrogen and progestins, and
to be downregulated by anti-oestrogens [25]. The tran-
scription of ER-regulated genes is also modulated by
Figure 2
Strong immunopositivity of BRCA1 tumour for p53 protein.http://breast-cancer-research.com/vol1no1/27oct99/review/3
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cyclin D1 [26,27]. Overexpression of cyclin D1 is a
common event in breast cancer and is especially frequent
in early onset breast cancer, probably because of high
levels of oestrogens in this age group [28]. BRCA1/BRCA2-
associated tumours show very low expression of cyclin D1
in both the invasive and in-situ components, however
(14% in both invasive and ductal carcinoma in situ compo-
nents in BRCA1/BRCA2 tumours, versus 35–36% in inva-
sive/ductal carcinoma in situ in sporadic tumours) [8•].
Taken together with the absence of ER and PgR in
BRCA1/BRCA2 cancers, the absence of cyclin D1 in these
tumours could be additional evidence of hormone inde-
pendence of BRCA-associated familial breast cancers.
Miscellaneous markers
Disruption of normal regulation of the cell cycle leading to
increased mitotic activity is a manifestation of tumourige-
nesis. In addition to traditional counting of mitotic figures,
a number of immunohistochemical methods have become
a part of routine tumour investigation. A high proliferative
index in BRCA-associated tumours compared with a grade-
matched control group has been demonstrated [1••,2•],
and recent studies [11••] have confirmed it by demonstrat-
ing high Ki67 labelling index (83 versus 48%).
Cathepsin D belongs to a family of proteases that are
involved in the tissue remodelling. Overexpression of
cathepsin D in breast cancer has been found to correlate
with poor prognosis [29–31] and the expression of cathep-
sin D in host stromal cells is associated with higher intra-
tumoural microvessel density [32]. Expression of
cathepsin D in BRCA1/BRCA2-associated breast cancers
was not found to be different from that in sporadic breast
cancers in two studies [11••,12•].
E-cadherin, an epithelial adhesion molecule is mutated at
high frequency in invasive lobular carcinoma [3,4]. Epi-
demiological studies have shown a link between familial-
ity and lobular carcinoma, although this does not appear to
be a phenotype of either BRCA1 or BRCA2 cancer. Inves-
tigation of E-cadherin expression in familial breast cancer
is limited, and there is no evidence at present that there
are any significant differences between familial and spo-
radic cancers [11••].
Conclusion
The study of familial breast cancer using immunohisto-
chemistry and molecular techniques is in its infancy. The
studies suggest that BRCA1-associated tumours are more
likely to be steroid receptor negative, and more often
express p53 protein. Mutations in TP53 also appear to be
increased in BRCA1 tumours. Although the data on
BRCA2-associated tumours are limited at present, they
appear to be different from BRCA1 tumours with respect
to ER and PgR. There is no evidence that the expression
of ER and PgR is different between sporadic cancers and
BRCA2-associated cancers. The data on p53 alterations in
BRCA2-associated tumours requires further clarification.
Combining data regarding the morphological types and
immunophenotypes of familial breast cancers indicates
that BRCA1 tumours are different from BRCA2 tumours
and sporadic cancers, and that the biological functions of
the proteins these genes encode are likely to be different.
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